Clinical trials: Pharmacokinetics of Enzalutamide
Prostate Cancer
A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate Cancer
The primary purpose of this study is to determine the effect of multiple once daily administrations of enzalutamide on the pharmacokinetics of a single dose of digoxin (P-glycoprotein (P-gp) substrate) and rosuvastatin (breast…
- Trial name
- NCT04094519
- Testing
- enzalutamide, digoxin, rosuvastatin
- Where
- Moldova
- Volunteers
- 24 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Advanced Solid Malignancies, Non-Small Cell Lung Cancer (NSCLC)
A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies
This is a Phase 1, open-label, multicenter study of continuous oral dosing of AZD4635 administered to patients with advanced solid malignancies.
- Conditions
- Advanced Solid Malignancies, Non-Small Cell Lung Cancer (NSCLC), Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC), Colorectal Carcinoma (CRC)
- Trial name
- NCT02740985
- Testing
- AZD4635, Durvalumab, Abiraterone Acetate
- Where
- 17 sites in United States
- Volunteers
- 313 people
- Sponsor
- AstraZeneca
Metastatic Castration-Resistant Prostate Cancer
A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer
This is an open label, non-randomized, Phase 1b/2a, dose escalation and dose confirmation study of ZEN003694 in combination with enzalutamide in patients with mCRPC.
- Trial name
- NCT02711956
- Testing
- ZEN003694, Enzalutamide
- Where
- 8 sites in United States
- Volunteers
- 75 people
- Sponsor
- Zenith Epigenetics
Healthy Subjects, Pharmacokinetics of MDV3100
A Study to Explore the Routes of Elimination of MDV3100
A study to investigate the excretion routes of radio-labelled MDV3100.
- Trial name
- NCT01911715
- Testing
- MDV3100
- Where
- Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
mCRPC
AXT-1003 Combination With Enzalutamide in Participants With mCRPC
The purpose of this study is to evaluate the efficacy, and safety of AXT-1003 combined with Enzalutamide in subjects with advanced prostate cancer.
- Trial name
- NCT07897071
- Testing
- AXT-1003, Enzalutamide
- Where
- 4 sites in China
- Volunteers
- 105 people
- Sponsor
- Axter Therapeutics (Beijing) Co., Ltd
Solid Tumours
Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer
This study aims to evaluate the combination of GSK525762 with other agents that have been shown to be effective in the treatment of CRPC or metastatic (m)CRPC.
- Trial name
- NCT03150056
- Testing
- GSK525762, Abiraterone, Enzalutamide
- Where
- 20 sites in United States, Australia and 2 more
- Volunteers
- 73 people
- Sponsor
- GlaxoSmithKline
Castration-Resistant Prostate Cancer
Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients
This is a Phase 1, open-label, multicenter study of KPG-121 administered orally once daily (QD) in 28-day treatment cycles to adult subjects.
- Trial name
- NCT03569280
- Testing
- Enzalutamide or Abiraterone or Apalutamid
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Kangpu Biopharmaceuticals, Ltd.
Metastatic Castrate-Resistant Prostate Cancer
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer
This study consists of two phases: Dose Escalation (Phase 1b) and Dose Expansion (Phase 2) The Dose Escalation phase will characterize the safety, tolerability, and determine the maximum tolerated dose (MTD) of alobresib as a…
- Trial name
- NCT02607228
- Testing
- Alobresib, Enzalutamide
- Where
- 4 sites in United States
- Volunteers
- 31 people
- Sponsor
- Gilead Sciences
Pharmacokinetics of Dextromethorphan, Pharmacokinetics of Caffeine
A Study to Evaluate How Daily Dosing With Enzalutamide Affects the Metabolism of Caffeine and Dextromethorphan in Men With Prostate Cancer
This study evaluates how once daily enzalutamide affects the metabolism of caffeine and dextromethorphan in men with prostate cancer by measuring concentrations of these drugs and their metabolites in plasma.
- Conditions
- Pharmacokinetics of Dextromethorphan, Pharmacokinetics of Caffeine, Prostate Cancer
- Trial name
- NCT02225093
- Testing
- Caffeine, Dextromethorphan, Enzalutamide
- Where
- Moldova
- Volunteers
- 12 people
- Sponsor
- Astellas Pharma Europe B.V.
Pharmacokinetics of MDV3100, Castration Resistant Prostate Cancer (CRPC)
Drug-drug Interaction Study With MDV3100 and a Cocktail of Substrates
A drug-drug interaction study to investigate the potential pharmacokinetic interaction between MDV3100 and a cocktail of substrates for pioglitazone (CYP2C8 substrate), S-warfarin (CYP2C9 substrate), omeprazole (CYP2C19…
- Trial name
- NCT01911728
- Testing
- MDV3100, Pioglitazone, Warfarin
- Where
- 2 sites in South Africa
- Volunteers
- 14 people
- Sponsor
- Astellas Pharma Europe B.V.
Neoplasms
A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
The goal of this clinical trial is to test a new medicine called GSK5764227, which delivers a toxin directly to cancer cells to destroy them while sparing healthy cells.
- Trial name
- NCT07277270
- Testing
- GSK5764227, Bevacizumab, Fluorouracil
- Where
- 22 sites in United States, Australia and 4 more
- Volunteers
- 83 people
- Sponsor
- GlaxoSmithKline
Pharmacokinetics of MDV3100, Healthy Subjects
Hepatic Impairment Study With MDV3100 in Subjects With Mild and Moderate Hepatic Impairment Compared to a Healthy Control Group
This study will assess the influence of hepatic impairment on the pharmacokinetics, safety and tolerability of a single dose of MDV3100 in male subjects. The study will consist of two treatment arms.
- Conditions
- Pharmacokinetics of MDV3100, Healthy Subjects, Kidney Diseases
- Trial name
- NCT01901133
- Testing
- MDV3100
- Where
- Moldova
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Severe Hepatic Impairment, Normal Hepatic Function
A Study to Investigate the Effect of Severely Diminished Liver Function on the Metabolism, Safety, and Tolerability of a Single Oral Dose of Enzalutamide in Men
The influence of severely diminished liver function on the metabolism, safety, and tolerability of a single oral dose of enzalutamide in a group of 8 men.
- Trial name
- NCT02138162
- Testing
- enzalutamide
- Where
- Bulgaria
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Drug-Drug Interaction (DDI), Healthy Subjects
A Study to Evaluate How a Drug That Alters Liver Enzymes (Rifampin) Affects the Metabolism of Enzalutamide in Men
This study evaluates how a drug that alters liver enzymes (rifampin) affects the metabolism of enzalutamide in men by measuring concentrations of enzalutamide and its metabolites in plasma.
- Conditions
- Drug-Drug Interaction (DDI), Healthy Subjects, Pharmacokinetics of Enzalutamide
- Trial name
- NCT02138799
- Testing
- enzalutamide, rifampin
- Where
- Germany
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Prostate Cancer
A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed in Men With Prostate Cancer
Hormone therapy, or androgen deprivation therapy (ADT) is a standard way to treat prostate cancer. It works by reducing the amount of testosterone in the body. One of the side effects of hormone therapy is hot flashes.
- Trial name
- NCT07783282
- Testing
- fezolinetant, enzalutamide, apalutamide
- Where
- Bulgaria
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Global Development, Inc.
Metastatic Castration Resistant Prostate Cancer
Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP)
Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib in Combination with Other Anticancer Agents in Patients with Metastatic Castration Resistant Prostate Cancer
- Trial name
- RAMP (NCT04179396)
- Testing
- Rucaparib, Enzalutamide, Abiraterone
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- pharmaand GmbH
Healthy Subjects, Pharmacokinetics
Drug-drug Interaction Study With MDV3100 (ASP9785) and Gemfibrozil and Itraconazole
A study to assess possible drug-drug interactions between MDV3100 and gemfibrozil and MDV3100 and Itraconazole.
- Conditions
- Healthy Subjects, Pharmacokinetics, Drug-Drug Interaction
- Trial name
- NCT01913379
- Testing
- MDV3100, Gemfibrozil, Itraconazole
- Where
- France
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Metastatic Castration Resistant Prostate Cancer
A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer
The purpose of this study is to assess the safety and tolerability, describe the dose-limiting toxicities (DLTs), and determine the maximum tolerated dose (MTD) or maximum administered dose (MAD [in the absence of establishing…
- Trial name
- MEDI3726 (NCT02991911)
- Testing
- MEDI3726 Post-Chemo, MEDI3726 Pre-Chemo, MEDI3726 & Enzalutamide Combo
- Where
- 5 sites in United States, Switzerland and 1 more
- Volunteers
- 33 people
- Sponsor
- MedImmune LLC
Metastatic Castration-Resistant Prostate Cancer
Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer
This study consists of a dose escalation study with an expansion phase to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD), and preliminary efficacy of exicorilant (CORT125281) in combination…
- Trial name
- NCT03437941
- Testing
- Exicorilant, Enzalutamide
- Where
- 9 sites in United States, United Kingdom
- Volunteers
- 39 people
- Sponsor
- Corcept Therapeutics
Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet…
- Conditions
- Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
- Trial name
- NCT07028853
- Testing
- Mevrometostat, Enzalutamide
- Where
- 319 sites in United States, Argentina and 24 more
- Volunteers
- 1,000 people
- Sponsor
- Pfizer